MD Biosciences Blog

MD Biosciences Expands into New State-of-the-Art

Research Facilities                 

(New research facilities to play pivotal role in Life Sciences Innovation)

St. Paul, Minn, (11.28.2016) - MD Biosciences announces its moves to new, expanded facilities in the United States and Israel. The larger research facilities will enable MD Biosciences to accommodate its growing clinical and preclinical services, its collaborative research and development activities, plus its growing drug development programs.

The new, purpose-built facilities feature state-of-the-art in vivo and in vitro laboratories, including larger space resources for CLIA proteomic and genomic analyses, and clinical flow cytometry work. The MD Biosciences histology and pathology laboratories have also been expanded to provide more complex GLP capabilities in the CNS, skin, immune-oncology and inflammatory therapeutic areas. To further accommodate specific project requirements - the new facilities also feature extensive Class 100 cleanrooms. 

As part of the new US facility, MD Biosciences will serve as the core anchor for Incubology, Inc., the new science park and incubator facility located in Oakdale, just east of Saint Paul, Minnesota. Incubology will host start-up and established companies from the pharma, medtech, chemistry and healthcare data sectors.

About MD Biosciences

MD Biosciences is a research and development company founded in 1991 with four business divisions. MD Biosciences CLIA laboratory provides assay development and clinical testing services for clinical stage programs. MD Biosciences Preclinical Services provide contract research services for drug development in areas including immuno-oncology, CNS, inflammatory and metabolic diseases. Early stage compounds in the area of neuropathic pain and cancer are being developed through MD Biosciences Innovalora Ltd. Finally, MD Biosciences is a manufacturer and distributor of proprietary products for industrial and academic drug discovery laboratories.

Contact: Jane Smith

MD Biosciences Inc.
1 Imation Way          
Oakdale, MN 55128
Toll Free: 888-876-3246 or 651-641-2881
Email    

MD Biosciences in-licenses intellectual property assets relating to colorectal cancer diagnostic methods of Bio-Marcare Technologies

(Blood-based Colon Cancer Screening Methodology)

October 14, 2016, Weizmann Science Park, Nes Ziona, Israel - MD Biosciences announced today its agreement for the exclusive license rights of all intellectual property assets of Bio-Marcare Technologies, Ltd. that relate to methods for circulating, DNA-based identification of pre-cancerous colorectal polyps and colorectal cancer. This agreement has been reached with Hadasit Medical Research Services and Development Ltd. of the Hadassah Ein Kerem Medical Center in Jerusalem, Israel.

MD Biosciences clinical scientists will be developing the methods towards commercialization at its CLIA clinical laboratories. “We are very excited to move forward with the development of the technology to provide a sensitive and cost-effective method for identifying and monitoring individuals at high risk of colorectal cancer, said Eddie Moradian, Chief Executive Officer of MD Biosciences. “A large percentage of individuals do not readily comply with current colon cancer screening methods and they would readily benefit from our blood-based tests.” 

Development work will be carried out at MD Biosciences Innovalora in Israel in conjunction with the MD Biosciences CLIA Clinical Diagnostics Laboratories in Saint Paul, MN.

About MD Biosciences

MD Biosciences is a research and development company founded in 1991 with four business divisions. MD Biosciences CLIA laboratory provides assay development and clinical testing services for clinical stage programs. MD Biosciences Preclinical Services provide contract research services for drug development in areas including immuno-oncology, CNS, inflammatory and metabolic diseases. Early stage compounds in the area of neuropathic pain and cancer are being developed through MD Biosciences Innovalora Ltd. Finally, MD Biosciences is a manufacturer and distributor of proprietary products for industrial and academic drug discovery laboratories.

St. Paul, Minn., September 6, 2016 - MD Biosciences announces its attendance at the 13^th International Society of Neuroimmunology (ISNI) Congress at the International Convention Center, Jerusalem, Israel – Sept., 26-29, 2016. The ISNI congress is a biennial event which gathers neuroimmunology experts from around the world to present the latest developments and revolutions in the field.

Isaac Levi, Ph.D., Director of MD Biosciences Neurology Laboratories will present recent findings on the assessment of sensory nervous system activity in awakened MOG induced EAE animals, titled “The function of pain associated fibers in MOG induced EAE”.

MD Biosciences has over 20 years of experience in the areas of inflammation, CNS and pain, with an emphasis on the interplay between these systems. To arrange a meeting with MD Biosciences at the event, contact us at info-us@mdbiosciences.com.

About MD Biosciences

MD Biosciences is a discovery and clinical stage pharmaceutical and biotechnological company. Over the course of 25+ years, MD Biosciences has developed a platform based on scientific expertise and knowledge, plus proprietary methodologies. Its platform is based on a deep understanding of inflammatory and immunological pathways, as well as neurological processes leading to disease states and therapeutic approaches. This knowledge is applied to the development of novel therapeutics, diagnostics as well as medical devices. MD Biosciences develops its own pipeline of compounds, develops and provides products for life science research, operates a clinical diagnostic assays laboratory and provides selective services through its contract research arm.  

4th Annual Immuno-Oncology Summit, Boston, MA

St. Paul, Minn., July 1, 2016 - MD Biosciences, announces its presence at the 4^th annual Immuno-Oncology Summit at the Marriott Long Wharf, Boston, MA - Aug. 29 – Sept. 2, 2016.

Britnie James, Ph.D., Director of the MD Biosciences Immunology Laboratories will present recent data on the impact of different animal supply and the microbiome in tumor progression and treatment studies. “Understanding the Impact of Animal Vendors and the Microbiome - in Tumor Progression and Treatment - in a Model of Metastatic Breast Cancer” will be presented at 10:00 am Wed., August 31.

Microbiome-related Studies 

MD Biosciences’ recent microbiome-related studies focused on animal vendor differences in the microbiome to identify any related impact in immunological and cellular functions. “We have examined whether  animals from different vendors, with discrete microbiomes, would  present with different disease progression and therapy responses in a  murine model of metastatic breast cancer,” said Britnie James. “I will be  presenting these research findings at the Immuno-Oncology Summit.”

Therapeutic Progress

According to Eddie Moradian, PhD, Chief Executive of MD Biosciences, “The impact of the microbiome on disease and therapy progression is becoming more evident. The microbiome may play an important role in the preclinical setting and possibly in the clinical settings as well. We hope to contribute to the understanding of the microbiome and its intricate relation to therapeutic progress with our research.”

More Information

For more information on the upcoming event visit Immuno Oncology Summit. To arrange a meeting with MD Biosciences at the event, contact us at info-us@mdbiosciences.com

About MD Biosciences

MD Biosciences is a discovery and clinical stage pharmaceutical and biotechnological company. Over the course of 25+ years, MD Biosciences has developed a platform based on scientific expertise and knowledge, plus proprietary methodologies. Its platform is based on a deep understanding of inflammatory and immunological pathways, as well as neurological processes leading to disease states and therapeutic approaches. This knowledge is applied to the development of novel therapeutics, diagnostics as well as medical devices. MD Biosciences develops its own pipeline of compounds, develops and provides products for life science research, operates a clinical diagnostic assays laboratory and provides selective services through its contract research arm.  

St. Paul, Minn., June 24, 2016 - MD Biosciences launches the InnovX^®research platform that’s designed to bridge the gap between preliminary, early stage and industry relevant life science product research discoveries by academic institute researchers, as well as de-risk necessary research investments.

InnovX® Platform Research in the focus areas of pharmaceuticals, medical devices and related biotechnologies are eligible for selection into the MD Biosciences development InnovX^® Platform program. Once academic institutional researchers seeking sponsorship are accepted into the MD Biosciences program, they enter into a full partnership agreement. The partnership includes access to a large library of resources, business and technology management expertise, and a vast network of industry contacts to help accelerate innovative life science technology developments.

InnovX^® - Novel Partner-based Platform

According to Eddie Moradian, Chief Executive Officer, at MD Biosciences, “The InnovX^® Platform is a novel partner-based approach to selecting and advancing promising technologies to a developmental stage that’s ripe for consideration by pharmaceutical and industrial partners. MD Biosciences will invest into the developmental phase from which traditional VC’s shy away from, namely the so-called Valley of Death.” He further added, “ We believe this investment strategy will bring significant value to all parties involved and will help to bring important technologies to light which may otherwise languish due to the lack of strategic investment and funding.”

Expediting the Commercialization Process

The InnovX^® Platform expedites the commercialization process of university developed assets by integrating development and entrepreneurship in multiple internal parallel projects. With our focused and lean approach, MD Biosciences will continue to invest in necessary research that will advance a technology for out-licensing, partnership or start-up formation.

The InnovX^® Platform is currently in advanced discussions with a number of high-ranking academic institutions in the US and other countries.

About MD Biosciences

MD Biosciences is a discovery and clinical stage pharmaceutical and biotechnological company. Over the course of 25+ years, MD Biosciences has developed a platform based on scientific expertise and knowledge, plus proprietary methodologies. Its platform is based on a deep understanding of inflammatory and immunological pathways, as well as neurological processes leading to disease states and therapeutic approaches. This knowledge is applied to the development of novel therapeutics, diagnostics as well as medical devices. MD Biosciences develops its own pipeline of compounds, develops and provides products for life science research, operates a clinical diagnostic assays laboratory and provides selective services through its contract research arm.  

Saint Paul, MN March 10, 2016

MD Biosciences announces that it will proceed with the Zika test services following clarification with the FDA regarding any pre-market approval requirements pertaining to this assay. Testing services will not be offered pending this clarification.

Zika Virus Test Update: Saint Paul, MN March 10, 2016

MD Biosciences announces that it will proceed with the Zika test services following clarification with the FDA regarding any pre-market approval requirements pertaining to this assay. Testing services will not be offered pending this clarification.

Saint Paul, MN, USA - February 29, 2016, - MD Biosciences, Inc. (mdbiosciences.com) Clinical and Diagnostics Services Laboratory announces the release of its rapid assay to detect the virus in human blood and urine samples. The nucleic acid test can be performed in a few hours in blood, plasma, serum or urine samples. The test is specific for the Zika virus and was shown not to cross react with other infectious viruses such as Dengue, West Nile or Chikunguya. The laboratory developed test is available immediately

The World Health Organization stated that the spread of the mosquito-borne virus will grow explosively throughout the Americas. According to the CDC, the virus has also been shown to be transmitted through sexual contact. Upwards of four million infections are expected in the region. Close to 80% of infections are asymptomatic while others suffer from fever, rash, joint aches and other hallmarks. A steep increase in birth defects and Guillain-Barre syndrome has correlated to the spread of the virus. The explosive spread of the virus, along with major crowd and traveller-related events such as this year’s Olympic Games in Brazil, have underscored the need for steps in fighting the spread of the virus, including the ability to rapidly and specifically identify the infection.

Eddie Moradian, Chief Executive Officer at MD Biosciences, stated, “We are extremely proud of our CLIA diagnostics laboratory’s ability to provide a reliable, accurate and rapid method of testing for Zika virus. This demonstrates our commitment in placing our expertise, knowledge and infrastructure for the betterment of health, in the US and throughout the world, whether through the development of more advanced diagnostics or by advancing newer, better and more efficient therapies."

About MD Biosciences

MD Biosciences is a leading provider of clinical and preclinical services with over 25 years of experience in the clinical diagnostics and preclinical research areas. Services are provided for cancer, inflammatory, metabolic and neurological diseases. MD Biosciences laboratories provide extensive experience in working with biomarkers and developing validated laboratory assays. MD Biosciences operates through its facilities and laboratories in the United States, Switzerland and Israel.

Located in Saint Paul, MN, MD Biosciences' Clinical and Diagnostics Services Laboratory is a CLIA accredited laboratory for high complexity testing. All testing is performed under stringent guidelines in state of the art laboratories. Other services include clinically relevant tests for genetic markers of diseases including various cancers.

Inquiries may be directed to: Susan Belzer, Vice President, MD Biosciences Clinical Diagnostics Laboratory

by e-mail: clinlab@mdbiosciences.com

by telephone to 1-888-USMDBIO (1-888-876-3246) or (651-641-1770).

ST. PAUL, Minnesota - January 25, 2016 - MD Biosciences (mdbiosciences.com) today announced the addition of its suite of in vivo and in vitro cancer models to its family of preclinical contract research services. MD Biosciences' oncology research program specializes in murine solid tumors for subcutaneous and orthoptopic models (for example, advanced breast cancer and renal cancer) with a specific focus on the immune aspects of disease development and progression. The comprehensive services include both syngeneic and xenograft models with readouts for longitudinal tumor monitoring (for some models), longitudinal blood phenotyping (immune cell distribution, biomarkers, etc.), endtime-point primary/metastic tumor evaluation, tumor tissue-specific cellular analysis using intravascular staining (cells: epithelial, endothelial, immune, etc.), biomarker analysis (blood, tumor, tissue, spleen, lymph node, etc.) and histological grading and evaluation of tumor specific issue (H&E, IHC, etc.).

"Our onco-immunology research team is comprised of skilled scientists with deep-rooted expertise in a highly complex field," said Eddie Moradian, MD Biosciences CEO. "We at MD Biosciences are excited to bring our high level of expertise and our novel models to assist sponsors and partners in reaching their programs' developmental goals. This new suite of capabilities compliments our existing, best-in-class services in other disease areas.

About MD Biosciences

MD Biosciences is a leading provider of preclinical services in the core areas of inflammation, immunological, neurologoical and metabolic diseases. The suite of services includes a wide range of cell-bassed assays, in vivo disease models, translational models as well as models for the indentification of the mode of action of drugs. The services are supported by CLIA accredited and GLP in vitro diagnostic laboratories for the testing of samples by using genomic and proteomic methods. MD Biosciences' in vitro laboratories provide services for the testing of clinical samples. Proprietary models include pig models for neuropathic pain, would healing and other key disease areas.